CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.

Autor: Cai, Ming-Ci1 (AUTHOR), Cheng, Shu1 (AUTHOR), Wang, Xin2 (AUTHOR), Hu, Jian-Da3 (AUTHOR), Song, Yong-Ping4 (AUTHOR), Huang, Yao-Hui1 (AUTHOR), Yan, Zi-Xun1 (AUTHOR), Jiang, Yu-Jie2 (AUTHOR), Fang, Xiao-Sheng2 (AUTHOR), Zheng, Xiao-Yun3 (AUTHOR), Dong, Li-Hua4 (AUTHOR), Ji, Meng-Meng1 (AUTHOR), Wang, Li1,5 (AUTHOR), Xu, Peng-Peng1 (AUTHOR), Zhao, Wei-Li1,5 (AUTHOR) zhao.weili@yahoo.com
Zdroj: Genome Medicine. 4/30/2020, Vol. 12 Issue 1, p1-13. 13p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje